Pinnacle Medicines

About Pinnacle Medicines

Pinnacle Medicines is a biotechnology company established in 2024, focusing on the development of a new generation of oral peptide therapeutics. The company was incubated by the healthcare investment firm OrbiMed. Based in Doylestown, Pennsylvania, and Shanghai, China, Pinnacle aims to create treatments that offer the efficacy of biologics with the convenience of an oral pill. The company's formation was a mutual effort between its co-founders and OrbiMed, which sought to incubate an oral peptide company.

The leadership team includes co-founder and Chief Scientific Officer Chengzao Sun, Ph.D., and co-founder and Chief Technology Officer Sandeep Somani, Ph.D., who previously worked together at Johnson & Johnson on peptide drug development. Jonathan Wang serves as the Chief Executive Officer, bringing over 15 years of experience from roles at Zai Lab, OrbiMed, Boston Consulting Group, and Goldman Sachs. Dr. Sun has over two decades of experience in peptide drug discovery at companies like Amylin, Merck, and Johnson & Johnson. Dr. Somani has more than 20 years of experience in computational chemistry applied to various drug modalities.

Pinnacle has developed a proprietary drug discovery platform called PinPoint, which is powered by PinSilico, a suite of technologies integrating physics-based molecular simulations and artificial intelligence. This platform is designed to rationally engineer and optimize peptide medicines, focusing on properties like affinity, stability, and permeability to ensure they can be taken orally. The company's business model revolves around discovering and advancing a pipeline of potential first-in-class and best-in-class oral peptide programs. The initial focus is on targeting validated pathways in immunology and cardiometabolic diseases, including conditions like asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, atopic dermatitis, and obesity.

Financially, Pinnacle Medicines has raised a total of $134 million. This includes a substantial Series A funding round led by OrbiMed and Qiming Venture Partners, followed by an oversubscribed $89 million Series B financing in March 2026. The Series B round was co-led by LAV and Foresite Capital, with participation from new and existing investors such as Quan Capital, RA Capital Management, and OrbiMed. These funds are intended to advance the company's lead programs through clinical proof-of-concept and to further expand its research and development capabilities. The company expects to move its lead asset into clinical trials by the end of 2026.